Hormone Receptor Positive Breast Cancer : Reviewing Abstracts Published by Authors Antonio Llombart-Cussac & Joan Albanell
Dr. Mansi Shah, Medical Oncologist, Ahemdabad
PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer
Author: Antonio Llombart-Cussac
Citation: Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1007-1007
LBA19 - GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC
Author: Joan Albanell
Citation: Annals of Oncology (2020) 31 (suppl_4): S1142-S1215.